Cerity Partners’s Summit Therapeutics SMMT Stock Holding History

Cerity Partners’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.67M	Buy	114,505 +719	+0.6%	+$12.8K	﹤0.01%	1692
2026 Q1	$2.16M	Buy	113,786 +908	+0.8%	+$14.7K	﹤0.01%	1448
2025 Q4	$1.97M	Sell	112,878 -1,779	-2%	-$33.5K	﹤0.01%	1374
2025 Q3	$2.37M	Sell	114,657 -187	-0.2%	-$4.54K	﹤0.01%	1217
2025 Q2	$2.44M	Buy	114,844 +1,190	+1%	+$27.1K	﹤0.01%	1123
2025 Q1	$2.19M	Buy	113,654 +440	+0.4%	+$8.83K	﹤0.01%	1082
2024 Q4	$2.02M	Buy	113,214 +13,772	+14%	+$267K	﹤0.01%	1097
2024 Q3	$2.18M	Buy	+99,442	New	+$1.39M	﹤0.01%	1056

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cerity Partners's SMMT Position: Q2 2026 in Review

Cerity Partners increased its Summit Therapeutics (SMMT) stake by 0.63% in Q2 2026, buying an estimated $12.8K and bringing the position to 114,505 shares worth $1.67M. The position accounts for ﹤0.01% of the portfolio, ranked #1692.

Cerity Partners first reported a position in SMMT in Q3 2024 and has held it in 8 quarters since. The position peaked at $2.44M in Q2 2025. 224 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Cerity Partners held 114,505 shares of Summit Therapeutics worth $1.67M as of Q2 2026.
Cerity Partners bought 719 Summit Therapeutics shares in Q2 2026, an estimated $12.8K.
Summit Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #1692 holding.
Cerity Partners first reported a position in Summit Therapeutics in Q3 2024 and has held it in 8 quarters since.
Cerity Partners's Summit Therapeutics position peaked at $2.44M in Q2 2025.
224 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.